Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrecISE Network Study in Severe Asthma
NCT04129931Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Dec 2019
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Microbiome Therapeutics, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of medium-chain triacylglycerol oil, clazakizumab, OM-85, imatinib and cavosonstat in asthma (5 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Forced Expiratory Volume in One Second Percent Predicted at 16 weeks and Juniper Asthma Control Questionnaire at 16 weeks. Started Dec 2019; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04129931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04129931.